| 黄毅,李磊,王桢,等.嗜酸性粒细胞作为乳腺癌病人曲妥珠单抗相关输注反应的预测指标价值分析[J].安徽医药,2023,27(4):763-766. |
| 嗜酸性粒细胞作为乳腺癌病人曲妥珠单抗相关输注反应的预测指标价值分析 |
| Value of eosinophil percentage as a predictor of trastuzumab related infusion response in breast cancer patients |
| |
| DOI：10.3969/j.issn.1009-6469.2023.04.029 |
| 中文关键词: 嗜酸性粒细胞 乳腺肿瘤 输注，静脉内 曲妥珠单抗 输注反应 |
| 英文关键词: Eosinophils Breast neoplasms Infusions, intravenous Trastuzumab Infusion reactions |
| 基金项目:国家自然科学基金青年科学基金项目( 82103261)；皖南医学院校级科研项目( JXYY202259) |
|
| 摘要点击次数: 958 |
| 全文下载次数: 231 |
| 中文摘要: |
| 目的探讨嗜酸性粒细胞作为乳腺癌病人曲妥珠单抗相关输注反应的预测价值。方法回顾性分析黄山市人民医院 2019年 1月至 2021年 12月 174例连续住院女性病人，均接受初始 8 mg/kg曲妥珠单抗治疗量，评估输注反应(IRs)发生情况。结果 136例病人符合纳入研究条件，在 27.9%(38/136)病人中观察到 IRs，多因素 logistic分析结果显示体质量指数 ≥24 kg/m2和嗜酸性粒细胞百分比 ≤2%是病人发生 IRs的危险因素，嗜酸性粒细胞百分比预测 IRs的曲线下面积为 0.75［95%CI:(0.65，0.85)］，当截断值为 2.05时，灵敏度和特异度分别为 86.4%和 54.5%；联合 BMI后预测 IRs的曲线下面积提高至 0.80(0.72，0.88)，其对应的灵敏度和特异度分别为 78.8%和 72.8%。结论低嗜酸性粒细胞百分比可作为乳腺癌病人曲妥珠单抗相关输注反应的预测因素。 |
| 英文摘要: |
| Objective To explore the value of eosinophils as a predictor of trastuzumab-associated infusion reactions (IRs) in patients with breast cancer.Methods A total of 174 consecutively hospitalized female patients from January 2019 to December 2021 inthe People′s Hospital of Huangshan Ctiy who received the initial dose of trastuzub at 8 mg/kg were retrospectively analyzed to evaluatethe incidence of IRs.Results One hundred and thirty-six patients were eligible for inclusion and IRs was observed in 27.9% (38/136)of patients. Univariate analysis showed that BMI≥24 kg/m2 and low eosinophil percentage (≤2%) were associated with IRs (P=0.008). The area under the curve for predicting IRs by eosinophil percentage was 0.75 [95%CI: (0.65,0.85)], with a sensitivity and specificity of 86.4% and 54.5%, respectively, when the cut-off value was 2.05; the area under the curve for predicting IRs by combining BMI increased to 0.80 (0.72,0.88), and the corresponding sensitivity and specificity were 78.8% and 72.8%, respectively.Conclusion Eosinophil percentage can be used as predictive markers of trastuzumab -associated IRs in breast cancer patients. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
